CONMED CORP (CNMD)
Health Care · Surgical and medical instruments · NYSE
CONMED is a global medical technology company specializing in innovative surgical devices and equipment for minimally invasive procedures.
What CONMED CORP does
CONMED Corporation is a global medical technology company that develops and markets surgical devices and related equipment for minimally invasive procedures. The company provides a range of products used by surgeons and physicians in the specialties of orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
Themes: minimally invasive surgery, orthopedic surgery, endoscopy, electrosurgery
Fundamentals
- Price$51.07 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- 1-year return-3.8% 2025-08-21 close $53.07 → 2026-08-21 close $51.07
- P/E26.36 as of 2026-08-24
- Net margin+4.1% as of 2026-08-24
- Gross margin+55.8% as of 2026-08-24
- ROE+5.5% as of 2026-08-24
- Debt / equity0.80 as of 2026-08-24
- Revenue growth (YoY)+3.4% as of 2026-08-24
- Revenue CAGR (3y)+9.6% SEC XBRL
- Beta0.96 as of 2026-08-24
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.7%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
How CNMD compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, CNMD's dividend was covered by reported results (earnings payout 53%, free-cash-flow payout 16%). This describes past coverage, not a forecast.
- Earnings payout53% dividends / net income
- Free-cash-flow payout16% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How CONMED CORP looks technically
CONMED CORP (CNMD) is trading 26.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day high about 15 trading days ago. Trading volume is unusually light — only about 40% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 26.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +26.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.78 | $41.78 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $40.32 | $40.32 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 48.41. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal | 5 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 26.7% above | +26.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control | 44.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 66.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($48.41 to $52.21) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 70.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $56.64 | $56.64 |
|---|---|---|
| From the 52-week high | it is 9.8% below its 52-week high (its highest price of the past year) | -9.8% |
| Above the 52-week low | it is 62.4% above its 52-week low (its lowest price of the past year) | +62.4% |
| Below the 52-week high | it is 9.8% below its highest point of the past year | 9.8% |
| Since a 20-day breakout | it made a new 20-day high about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 15 trading days ago | 15 sessions |
| All-time high | its highest closing price on record is $159.11 (set on 2021-11-05) | $159.11 |
| Given back of the 52-week move | over the past year its closes ranged ($32.11 to $55.81), and it has recovered almost all of its fall from last year’s high — 80% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $46.76 to $47.52. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 80.0% |
| From the all-time high | it is 67.9% below its all-time high | -67.9% |
| Nearest price level | it is trading 5.2% above a support level at $48.41 — a price it turned at three times since 2025-04-30, most recently on 2026-08-12. Since 2024-08-21 it has 9 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.2% |
| All-time low | its lowest closing price on record is $8.00 (set on 2000-08-23) | $8.00 |
| Above the all-time low | it is 538.4% above its all-time low | +538.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 56th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.97 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.97 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $43.76 and $53.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $43.76 – $48.78 – $53.80 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 5.5 daily ranges above its 200-day average price (26.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 40% of its 30-day average | 0.40× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 18 sessions ago and has not traded back through the level it left behind at 43.51 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.7% gap down opened on 2026-08-17 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 3 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 19.6 percentage points (the stock gained 21.9% while the market gained 2.3%) | +19.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 34.9 percentage points (the stock gained 38.0% while the market gained 3.1%) | +34.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 2.1 percentage points (the stock gained 13.1% while the market gained 11.1%) | +2.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 24.3 percentage points (the stock lost 3.8% while the market gained 20.5%) | -24.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 32% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.6% of the share price, which is taken to mean a barrier that gives way easily. | +32.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $40.06 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +27.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $49.01 — a volume-weighted average of daily closes over 18 sessions, not a true tick-by-tick VWAP. | +4.2% |
Price levels it has turned at before
CNMD last closed at $51.07 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $48.41 | Support | 5.2% below the last close | turned there three times · 2025-04-30 to 2026-08-12 |
| $47.20 | Support | 7.6% below the last close | turned there twice · 2025-07-21 to 2026-02-26 |
| $55.11 | Resistance | 7.9% above the last close | turned there five times · 2025-03-04 to 2025-08-13 |
| $56.38 | Resistance | 10.4% above the last close | turned there twice · 2025-08-22 to 2025-09-05 |
| $45.52 | Support | 10.9% below the last close | turned there five times · 2025-04-21 to 2026-07-16 |
| $60.17 | Resistance | 17.8% above the last close | turned there twice · 2025-05-01 to 2025-06-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $48.41.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $56.58 and $69.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · in a strong, established uptrend (ADX) · Trading above the Ichimoku cloud · Elliott wave 5 candidates | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$45.50 range $43.00 – $49.00; median $45.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CNMD
- Consensus EPS estimate$1.00 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on continued market acceptance of minimally invasive surgical procedures.","Risks associated with integrating acquired businesses and product lines.","Potential supply chain disruptions and fluctuations in raw material or component costs."]
What changed in the latest 10-Q
AI-assisted comparison of CNMD's 10-Q filed 2026-04-30 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing includes sale of gastroenterology product line assets for $7.0 million with $3.9 million gain recorded (Note 1, filed 2026-04-30)
- Newer filing shows repurchases of common stock totaling $37,387 thousand for three months ended March 31, 2026 (filed 2026-04-30)
- Newer filing includes 'Gain on sale of a product line' adjustment of $3,916 thousand in operating activities (filed 2026-04-30)
- Newer filing shows 'Proceeds from sale of a product line' of $7,000 thousand in investing activities (filed 2026-04-30)
- Removed:
- Older filing included nine months ended and year-to-date comparative data; newer filing shows only three months ended March 31 data (filed 2025-11-06 vs 2026-04-30)
- Older filing included 'Other expense' line item of $418 thousand for nine months ended September 30, 2025; not present in newer filing (filed 2025-11-06)
- Older filing included 'Loss on early extinguishment of debt' adjustment of $363 thousand; not present in newer filing (filed 2025-11-06)
- Older filing included 'Payments on term loan' of $79,821 thousand in financing activities for nine months ended; newer filing shows zero term loan payments for three months ended (filed 2025-11-06 vs 2026-04-30)
- Reworded:
- Newer filing Item 2 (MD&A) page reference changed from 21 to 19 (filed 2026-04-30)
- Newer filing Item 3 (Market Risk Disclosures) page reference changed from 28 to 25 (filed 2026-04-30)
- Newer filing Item 4 (Controls and Procedures) page reference changed from 28 to 25 (filed 2026-04-30)
- Newer filing Item 1 (Legal Proceedings) page reference changed from 28 to 25 (filed 2026-04-30)
- Newer filing removed 'Item 2. Unregistered Sales of Equity Securities and Use of Proceeds' section present in older filing (filed 2025-11-06)
- Newer filing Item 5 (Other Information) page reference changed from 28 to 26 (filed 2026-04-30)
- Newer filing Item 6 (Exhibits) page reference changed from 29 to 27 (filed 2026-04-30)
- Newer filing Signatures page reference changed from 30 to 28 (filed 2026-04-30)
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs Q3 2025) making direct financial comparison limited to structural and disclosure changes
- Newer filing text appears truncated at Note 2, limiting full assessment of notes comparison
- The comparison reflects quarterly vs. nine-month presentation differences between the filings
Risk Factors
- Added:
- Announcement on December 5, 2025 of intent to exit gastroenterology product lines as part of portfolio optimization strategy (filed 2026-04-30)
- Termination of distribution agreement with W.L. Gore & Associates, Inc. for Gore® VIABIL® biliary stent effective January 1, 2026 (filed 2026-04-30)
- Sale of certain gastroenterology assets during three months ended March 31, 2026 and remaining product lines during April 2026 (filed 2026-04-30)
- $1.9 million benefit from termination of Gore distribution agreement reflected in gross profit (filed 2026-04-30)
- $3.9 million benefit from gain on sale of gastroenterology assets reflected in selling and administrative expense (filed 2026-04-30)
- $3.3 million in cash and stock-based compensation costs for advisory services from former Chief Financial Officer in Q1 2026 (filed 2026-04-30)
- $7.5 million of consulting fees, legal fees and other costs related to operational optimization in Q1 2026 (filed 2026-04-30)
- $1.2 million in costs to comply with European Union's Medical Device Regulations in Q1 2026 (filed 2026-04-30)
- Reference to Form 10-K for year ended December 31, 2025 (filed 2026-04-30)
- Removed:
- Statement that CONMED would not be renewing Distribution Agreement with Gore after December 31, 2026 (filed 2025-11-06)
- Reference to Gore VIABIL device generating $44.1 million of net sales in nine months ending September 30, 2025 with 38% gross profit margin (filed 2025-11-06)
- Three and nine months ended September 30 financial data tables and commentary (filed 2025-11-06)
- Reference to Form 10-K for year ended December 31, 2024 (filed 2025-11-06)
- $19.7 million write-off of inventory, equipment, tooling and patents in 2025 (filed 2025-11-06)
- $12.3 million in consultant costs for supply chain and manufacturing evaluation in nine months ended September 30, 2025 (filed 2025-11-06)
- $8.5 million in consulting fees for operational optimization in nine months ended September 30, 2025 (filed 2025-11-06)
- $5.5 million in consulting fees for operational optimization in three months ended September 30, 2025 (filed 2025-11-06)
- Contingent consideration fair value adjustment amounts for 2024 and 2025 comparison (filed 2025-11-06)
- Reworded:
- Gore distribution agreement status changed from planned non-renewal after December 31, 2026 to completed termination effective January 1, 2026 with subsequent asset sales (filed 2026-04-30 vs 2025-11-06)
- Reporting period changed from three and nine months ended September 30, 2025/2024 to three months ended March 31, 2026/2025 (filed 2026-04-30 vs 2025-11-06)
- Gastroenterology sales context changed from general growth driver to product line being exited, with specific sales figures: $9.5 million Q1 2026 vs $25.0 million Q1 2025 (filed 2026-04-30)
- General surgery sales explanation changed from growth in AirSeal, Buffalo Filter and biliary offerings to decline due to gastroenterology product line exit (filed 2026-04-30 vs 2025-11-06)
- Notes:
- The newer filing covers Q1 2026 period while older filing covered Q3 2025 and nine-month periods, making direct period comparisons limited
- The documents compare different fiscal periods making some year-over-year discussions non-identical in structure
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CNMD — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CNMD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 6,466,416
- Reported value $228,652,452
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CNMD had 2,234,640 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CNMD had 7.46% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.47 days to cover at the same settlement.
- Reported short interest (shares) 2,234,640
- Short interest (% of shares outstanding) 7.46%
- Prior settlement (shares) 2,329,178
- Reported change -4.06%
- Days to cover (reported) 3.47
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Stryker (SYK)
- Smith & Nephew
- Johnson & Johnson (JNJ)
- Medtronic (MDT)
- Arthrex
- Olympus (OCPNY)
- Karl Storz
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CNMD vs…
CONMED CORP is found in…
Frequently asked questions
What does CONMED CORP (CNMD) do?
CONMED Corporation is a global medical technology company that develops and markets surgical devices and related equipment for minimally invasive procedures. The company provides a range of products used by surgeons and physicians in the specialties of orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
What sector is CONMED CORP (CNMD) in?
CONMED CORP (CNMD) is classified in the Health Care sector. Its industry is Surgical and medical instruments. It trades on NYSE.
Does CNMD pay a dividend?
Yes — CONMED CORP (CNMD) pays a dividend, with an indicated yield of about 0.74% and 1-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-08-24). Informational only — not financial advice.
Who are CONMED CORP's (CNMD) competitors?
Notable peers of CONMED CORP (CNMD) include Stryker, Smith & Nephew, Johnson & Johnson, Medtronic and Arthrex. This peer set is informational only — not financial advice.
Is CONMED CORP (CNMD) overbought or oversold right now?
CONMED CORP (CNMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CNMD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.